Amgen Inc (AMGN34) Fair Value & Analysis
Healthcare · BR · Market cap R$1.0T
Fair value as of: Jul 19, 2026
From 26 valuation models · updated 3 days ago
Share price +6.5% over the past month.
Price vs Fair Value (12 months)
12‑month range R$47.91 – R$77.69 · fair‑value band R$4.71 – R$13.10 · the R$66.34 price screens above the R$8.51 fair value. As of Jul 19, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Amgen Inc (AMGN34) currently trades at R$66.34, while our model-based Fair Value estimate is R$8.51, implying the stock looks roughly 87.2% overvalued today. We read business quality at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Amgen Inc generated revenue of R$37.2B at a net margin of 21.0%. Revenue grew 5.8% year over year. It earns a return on equity of 101.3%. Net debt stands at R$45.5B. Fundamentals as of Jul 19, 2026
Our scenario range runs from R$4.71 (bear case) to R$13.10 (bull case); at R$66.34, the current price sits above that range. The share trades about 15% below its 52-week high and 38% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at -87%, AMGN34 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 19, 2026. TTM = trailing twelve months.
About the company
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Amgen Inc reported revenue of R$36.8B in FY2025 versus R$26.0B in FY2021, a compound +9.1%/yr. Reported net income was R$7.7B in FY2025, compounding +7.0%/yr from FY2021.
Is AMGN34 fairly valued? → Check now
Recent news
- Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
- What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.
- Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
- Will Amgen (AMGN) Beat Estimates Again in Its Next Earnings Report?
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,102 | $395.92 | -64% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,944 MXN | -29% |
| AbbVie Inc ABBV | $224.95 | $129.90 | -42% |
| Roche Holding 1RO | €377.80 | €280.03 | -26% |
| Merck & Co MRCK34 | R$75.80 | R$13.54 | -82% |
| Novartis AG NVSN | 2,601 MXN | 1,897 MXN | -27% |
| AstraZeneca PLC ZEG | €160.70 | €109.08 | -32% |
| Novo Nordisk A/S NOVOB | kr 299.95 | kr 542.67 | +81% |
| Gilead Sciences, Inc GILD | 2,263 MXN | 2,205 MXN | -3% |
| Pfizer Inc PFE | C$11.60 | C$8.86 | -24% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Amgen Inc (AMGN34) undervalued?
What is the fair value of AMGN34?
What is the quality score of AMGN34?
What is the revenue of Amgen Inc (AMGN34)?
What is the net profit margin of AMGN34?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Amgen Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.